Manipal Health Enterprises Ltd (MANIPALHOS) — Announcement | 27 August 2026

· BSE 🔴 High Importance Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings
📢 Key Event
Q1 FY27 revenue grew 38% YoY to INR 3,091 crores with network EBITDA up 26% YoY to INR 749 crores
🔄 What Changed
Sahyadri EBITDA margin improved to 17.5% from prior period; digital revenue now 23% of total
🔮 What's Next
18-month Sahyadri integration plan; commissioning 50 new hospitals including Bangalore sites; Kinder Hospital acquisition potential in FY27
💡 Investor Takeaway
Shareholders should note near-term margin pressure from greenfield expansions but long-term growth is anchored in specialty center expansion and digital adoption.

Manipal Health Enterprises reported robust Q1 FY27 growth with revenue up 38% YoY to INR 3,091 crores and network EBITDA up 26% YoY to INR 749 crores, driven by volume expansion and specialty centers. Sahyadri Hospitals contributed INR 332 crores revenue at 17.5% EBITDA margin, showing sequential improvement. Management outlined an 18-month integration plan for Sahyadri, targeting 50 new hospitals including Bangalore expansions and Kinder Hospital acquisition, while focusing on oncology growth in Delhi NCR and clinical milestones like robotic pediatric surgery.

📄 View Original Announcement (PDF)

About Manipal Health Enterprises Ltd (MANIPALHOS)

Healthcare · Healthcare · Listed on BSE

Market Cap: ₹98,258.68 Cr

View full MANIPALHOS stock details →

📡 Get AI alerts when MANIPALHOS files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track MANIPALHOS — Free

📊 More MANIPALHOS filings

See all MANIPALHOS filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when MANIPALHOS files new disclosures

Track MANIPALHOS filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track MANIPALHOS — Free

Free account · 2 AI queries/day